Allergy & Asthma Network and Avella Specialty Pharmacy have released a white paper underscoring latex allergy risks and how that relates to the health care industry.
"Patient and physician safety is our highest priority, and we're pleased to collaborate with Allergy & Asthma Network to shine a spotlight on the risks related to latex allergies and the use of latex in health care," Avella Specialty Pharmacy CEO Rebecca Shanahan said in a statement. "Working in health care, it is vitally important to be aware of – and prepare for – all allergies related to the medications and products we use daily. We hope this white paper will equip caregivers with the information they need to ensure their safety and the safety of their patients."
According to the white paper, confusion exists as to products sold with “latex free” or “does not contain latex” labels. According to the U.S. Food and Drug Administration, the labels are not specific enough and not necessarily accurate scientifically, because it is challenging to ensure a product is 100 percent free of natural rubber latex. The FDA has therefore urged manufacturers to stop using the label.
"We commend Avella Specialty Pharmacy for its leadership around the important issue of safeguarding against adverse effects related to latex allergies and the use of latex in health care," Tonya Winders, president and CEO of Allergy & Asthma Network, said. "When working with patients who have latex allergies, healthcare personnel must make efforts to ensure a latex-safe environment and therapy regimen.”